>
N4 Pharma logo

N4P - N4 Pharma Share Price

8.31p -0.1  -1.1%

Last Trade - 8:24am

Sector
Healthcare
Size
Micro Cap
Market Cap £15.2m
Enterprise Value £11.7m
Revenue £n/a
Position in Universe 1519th / 1820
Bullish
Bearish
Unlock N4P Revenue
Momentum
Relative Strength (%)
1m -5.44%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -47.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 1.16 0.11 0.073 0.000 0.000 0.085
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, N4Pharma PLC revenues was not reported. Net loss increased49% to £1.3M. Higher net loss reflects Research anddevelopment costs increase from £217K to £900K (expense),Finance expenditure increase of 42% to £2K (expense). BasicEarnings per Share excluding Extraordinary Items remainedflat at -£0.01.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

N4P Revenue Unlock N4P Revenue

Net Income

N4P Net Income Unlock N4P Revenue

Normalised EPS

N4P Normalised EPS Unlock N4P Revenue

PE Ratio Range

N4P PE Ratio Range Unlock N4P Revenue

Dividend Yield Range

N4P Dividend Yield Range Unlock N4P Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
N4P EPS Forecasts Unlock N4P Revenue
Profile Summary

N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B. Its vaccines include Nuvac and Nuvec. The Company is improving Sildenafil for erectile dysfunction. Sartans is a family of drugs known as Angiotensin II antagonists, including Losartan and Valsartan, commonly used for the treatment of hypertension. Aprepitant is an anti-emetic drug used in oncology. It is reformulating the existing Hepatitis B surface antigen vaccine (HBsAg), a sub unit vaccine. Nuvac is a nano-carrier delivery system for vaccines. Nuvec is an engineered silica nanoparticle, which has been designed for the intracellular delivery of large nucleic acids such as plasmid deoxyribonucleic acid and messenger ribonucleic acid.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated July 6, 1979
Public Since June 7, 2005
No. of Shareholders: n/a
No. of Employees: 4
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 181,080,349
Free Float (0.0%)
Eligible for
ISAs
SIPPs
N4P Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for N4P
Upcoming Events for N4P
Frequently Asked Questions for N4 Pharma
What is the N4 Pharma share price?

As of 8:24am, shares in N4 Pharma are trading at 8.31p, giving the company a market capitalisation of £15.2m. This share price information is delayed by 15 minutes.

How has the N4 Pharma share price performed this year?

Shares in N4 Pharma are currently trading at 8.31p and the price has moved by 23.53% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the N4 Pharma price has moved by -1.32% over the past year.

What are the analyst and broker recommendations for N4 Pharma?

Of the analysts with advisory recommendations for N4 Pharma, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for N4 Pharma is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will N4 Pharma next release its financial results?

N4 Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the N4 Pharma dividend yield?

N4 Pharma does not currently pay a dividend.

Does N4 Pharma pay a dividend?

N4 Pharma does not currently pay a dividend.

When does N4 Pharma next pay dividends?

N4 Pharma does not currently pay a dividend.

How do I buy N4 Pharma shares?

To buy shares in N4 Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of N4 Pharma?

Shares in N4 Pharma are currently trading at 8.31p, giving the company a market capitalisation of £15.2m.

Where are N4 Pharma shares listed? Where are N4 Pharma shares listed?

Here are the trading details for N4 Pharma:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: N4P
What kind of share is N4 Pharma?

Based on an overall assessment of its quality, value and momentum, N4 Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a N4 Pharma share price forecast 2021?

We were not able to load any forecast data for N4 Pharma.

How can I tell whether the N4 Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like N4 Pharma. Over the past six months, the relative strength of its shares against the market has been -14.88%. At the current price of 8.31p, shares in N4 Pharma are trading at 7.24% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the N4 Pharma PE Ratio?

We were not able to find PE ratio data for N4 Pharma.

Who are the key directors of N4 Pharma?

N4 Pharma's management team is headed by:

Luke Cairns - NID
Nigel Theobald - CEO
David Templeton - EDR
John Chiplin - NEC
Christopher Britten - NED
Who are the major shareholders of N4 Pharma?

Here are the top five shareholders of N4 Pharma based on the size of their shareholding:

Theobald (Nigel James) Individual Investor
Percentage owned: 9.38% (17.0m shares)
Farrier (David John) Individual Investor
Percentage owned: 6.93% (12.5m shares)
First Equity Ltd. Corporation
Percentage owned: 1.93% (3.50m shares)
Redmayne-Bentley LLP Investment Advisor
Percentage owned: 0.24% (438k shares)
Kinner (Stuart Ronald) Individual Investor
Percentage owned: 0.09% (157k shares)
Similar to N4P
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.